Trial Profile
A study on circulating tumor DNA investigating the effect of crizotinib and KRAS and ALK mutations induced resistance to TKIs targeting ALK rearrangement
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Jul 2016
Price :
$35
*
At a glance
- Drugs Crizotinib (Primary) ; Ceritinib
- Indications Adenocarcinoma; Lung cancer; Non-small cell lung cancer
- Focus Therapeutic Use
- 27 Jul 2016 New trial record
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology